Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients

Journal of Critical Care

Volumn 26, Issue 1, 2011, Pages 104.e1-104.e6

  Rivkin, Anastasia ^a,b   Yin, Hongjun ^a  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Critical care; Drug drug interactions; Intensive care; Pharmacist

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ATORVASTATIN; CALCIUM CHLORIDE; CEFTRIAXONE; DILTIAZEM; EFAVIRENZ; EMTRICITABINE; ESOMEPRAZOLE; FENTANYL; FLUCONAZOLE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LEVOTHYROXINE; LINEZOLID; MIDAZOLAM; MIRTAZAPINE; MODAFINIL; PETHIDINE; PHENYTOIN; PROPOFOL; RISPERIDONE; SIMVASTATIN; TACROLIMUS; TENOFOVIR; TRAMADOL; UNINDEXED DRUG; WARFARIN;

AGED; ARTICLE; CLINICAL PHARMACY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MONITORING; DRUG POTENTIATION; FEMALE; HEALTH SERVICE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; PATIENT CARE; PROSPECTIVE STUDY;

EID: 79551508884     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.04.014     Document Type: Article

References (11)

1. Dubaybo B.A., Dingell J.D. Adverse drug reactions in the ICU: lessons learned. Chest 2005, 128:1100-1101.
2. Leape L.L., Bates D.W., Cullen D.J., et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995, 274:35-43.
3. Leape L.L., Cullen D.J., Clapp M.D., et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999, 282:267-270.
4. Luna D., Otero V., Canosa D., Montenegro S., Otero P., De Quiros F.G. Analysis and redesign of a knowledge database for a drug-drug interactions alert system. Stud Health Technol Inform 2004, 107(Pt 2):1367-1370.
5. Weingart S.N., Toth M., Sands D.Z., Aronson M.D., Davis R.B., Phillips R.S. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003, 24;163(21):2625-2631.
6. Isaac T., Weissman J.S., Davis R.B., Massagli M., Cyrulik A., Sands D.Z., Weingart S.N. Overrides of medication alerts in ambulatory care. Arch Int Med 2009, 169(3):305-311.
7. Cash J.J. Alert fatigue. Am J Health Syst Pharm 2009, 66(23):2098-2101.
8. Horn E., Jacobi J. The critical care pharmacist: evolution of an essential team member. Crit Care Med 2006, 34(Suppl.):S46-S51.
9. Preventable adverse drug reactions: a focus on drug interactions. Available at Accessed October 27, 2009. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm#Preventing%20Drug%20Interactions.
10. Jacubeit T., Drisch D., Weber E. Risk factors as reflected by an intensive drug monitoring system. Agents Actions 1990, 29:117-125.
11. Tleyjeh I.M., Kashour T., Hakim F.A., et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169(18):1658-1667.